Drugs / CNP-103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06783309 | May 2025 → Dec 2026 expected | type 1 diabetes mellitus | COUR Pharmaceutical Development Company, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNP-103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06783309 ↗ |
| Route | Intravenous | “IV administrations” NCT06783309 ↗ |